|Daily Range||$6.62 - $6.80|
|52-Week Range||$3.43 - $34.55|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||203,110|
|Current FY EPS||-$0.65|
Prosensa Holding B.V. (RNA) Description
Prosensa Holding B.V. Website: http://www.prosensa.eu/
News & Commentary
Amarin, Dendreon, and Prosensa are three biotech stocks which should be avoided at all costs. Here’s why.
2014 starts a dismal year for Duchenne prospects by Sarepta, Prosensa, PTC and Retrophin
Sarepta outlines the next steps for its revolutionary Duchenne muscular dystrophy-fighting pipeline. Should investors be excited?
The J.P. Morgan Healthcare Conference led to the release of five important clinical updates this week.
Sarepta Therapeutics and Prosensa shares increase dramatically with separate data releases. Did GlaxoSmithKline make a mistake letting Prosensa go?
Prosensa shares soar after it reported encouraging clinical findings for Duchenne muscular dystrophy drug drisapersen. Here's why investors might want to consider taking this "encouraging" news with a grain of salt.
Sarepta releases positive phase 2b data on its Duchenne muscular dystrophy drug, eteplirsen. Should shareholders jump on this data or approach it with caution?